凯发K8

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. (SZCV) is a one-stop CRO/CDMO service platform dedicated to the field of cell and gene therapy, as well as an integrated platform for the clinical translation and application of new biomedical technologies. The company was jointly founded by a team of returnee scientists from Harvard University, Cornell University, Columbia University, and the University of California, San Diego. SZCV focuses on core technologies including viral vectors, cell therapeutics, exosomes, and eVLP delivery systems, and possesses full-process capabilities from process development and GMP manufacturing to quality control. As a major public service platform for the biomedical industry in Shenzhen, its flagship project, the “One-stop Cell and Gene Therapy CRO/CDMO Service Platform – South China Cell Factory,” was selected as a 2022 Shenzhen Major Project. SZCV is also recognized as a Shenzhen Overseas High-level Talent Team, a Viral Vector Common Technology Research Platform under the National Engineering Research Center for Key Generic Technologies in the Cell Industry, a Commercialization Base of Shenzhen High-tech Zone Innovation Achievements Program, and serves as the Vice Chairman Unit of the Shenzhen Biomedical Industry-Education Alliance.